About this episode
In Part 1 of our conversation with David Moatazedi, President and CEO of Evolus, we cover the company's global vision and strategy, built on a shift from a traditional pharma model towards 'performance beauty'.
We discuss market differences by country, rapid trend cycles and the need for continuing clinical evidence. We also address the drop in global HA filler demand, macroeconomics, pipeline strategy, future modalities, AI and robotics, and Evolus' launch in Australia.
What you'll learn
- Evolus' growth strategy and the idea of 'performance beauty'
- How the aesthetics industry is maturing worldwide
- Hype cycles, the natural look and long-term staying power
- Why Evolus went public, and macro risks
- Why HA fillers have slowed, and rebranding the category
- The next waves of innovation, including AI and robotic injectors
- What aesthetics could look like in 2035
Topics
- Evolus
- Industry strategy
- Performance beauty
- HA fillers
- Innovation
- AI
- Market trends
- Australia launch
Full transcript
The full transcript for this episode is coming soon.